Completed PHASE2 NCT00065182

Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer

WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL

Sponsor: GlaxoSmithKline

Conditions Lung Cancer, Non-Small Cell Non-Small-Cell Lung Cancer

Interventions Docetaxel Topotecan/Docetaxel combination

Updated 8 times since 2017 Last updated: Mar 29, 2019 Started: Aug 14, 2003 Primary completion: Aug 30, 2007 Completion: Aug 30, 2007

A PHASE2 clinical study on Lung Cancer, Non-Small Cell and Non-Small-Cell Lung Cancer, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jul 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jul 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abingdon, United States , Baton Rouge, United States , Boca Raton, United States , Boston, United States , Bowling Green, United States , Buffalo, United States , Calgary, Canada , Canton, United States , Casper, United States , Columbia, United States and 69 more locations